argenx (ARGX) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revolution Medicines (RVMD) has outperformed argenx (ARGX) over the past year, gaining 331.3% versus a gain of 2.5%. Over five years, RVMD leads with a +645.3% price change compared with +178.7% for ARGX. argenx is the larger company by market cap ($51.48 billion vs $40.32 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | RVMD |
|---|---|---|
| Share price | $818.63 | $188.12 |
| Market cap | $51.48B | $40.32B |
| 1-day change | -11.83% | -6.35% |
| YTD return | -2.65% | +152.19% |
| 1-year return | +2.46% | +331.33% |
| 5-year return | +178.69% | +645.34% |
| P/E ratio (TTM) | 31.20 | — |
| Forward P/E | 23.58 | — |
| EPS (TTM) | $26.24 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $1.29B | $-1.13B |
| 52-week high | $1,072.75 | $224.31 |
| 52-week low | $661.85 | $47.28 |
| Distance from 52-week high | -23.69% | -16.13% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.17% | +37.59% |
| Average volume | 283.40K | 1.88M |
| Shares outstanding | 62.89M | 214.34M |
| Employees | 1,863 | 883 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVMD has outperformed ARGX by 328.9 percentage points over the past year.
- The two companies sit in different sectors: argenx in Healthcare and Revolution Medicines in Health Care.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
ARGX vs RVMD FAQ
Which is bigger, argenx or Revolution Medicines?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $40.32B for Revolution Medicines (RVMD).
Which stock has performed better over the past year, ARGX or RVMD?
RVMD returned +331.33% over the past 12 months, compared with +2.46% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Are argenx and Revolution Medicines in the same industry?
No. argenx is in the Healthcare sector, while Revolution Medicines is in Health Care.